Quantitative MHC class-I/-II gene expression levels in CDK12 mutated prostate cancer reveal intratumorally T cell adaptive immune response in tumors
W. Lautert-Dutra, C. M. Melo, L. P. Chavez, C. Crozier, F. P. Saggioro, R. B. dos Reis, J. Bayani, S. Bonatto, J. A. Squire
The paper examines MHC expression levels in CDK12 mutated prostate cancer and finds that higher MHC expression correlates with immune activation and T cell infiltration, while lower MHC expression is linked to genomic loss of heterozygosity and reduced immune response.
bioRxiv · Apr 16, 2022 · PreprintCancer Biology